Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited announced its unaudited consolidated results for the nine months ending September 30, 2025. The company reported a slight increase in operating income by 0.42% compared to the previous year, while net profit attributable to shareholders decreased by 25.53%. Despite the decline in net profit, the company experienced a 26.65% increase in net cash flow from operating activities, indicating improved operational efficiency.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company established in China, operating in the pharmaceutical industry. The company focuses on manufacturing and distributing pharmaceutical products.
Average Trading Volume: 3,387,304
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.43B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.